Back to search results
Completed

Psoriasis, Psoriatic Arthritis

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT P3)

RHBF | {{ defaultRegistry.registryAnchorText }} NCT02584855 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.

Completed Study

The results of this study are not yet available.

Time Commitment

Your participation could last up to 2.5 years and include 32 visits to the study center.

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study

Gender

Male Female

Age

18+ years
  • Participant must have a diagnosis of active psoriatic arthritis (PsA) for at least 6 months. Active PsA is defined as the presence of at least 3 tender and at least 3 swollen joints

  • Participant must have the presence of active psoriatic skin lesions or a history of plaque psoriasis (Ps)

  • Male participants must agree to use a reliable method of birth control or remain abstinent during the study

  • Female participants must agree to use reliable method of birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

  • Participant must have been previously treated with 1 or more conventional disease-modifying antirheumatic drugs (cDMARDs)

  • Participant must not be currently using more than one cDMARD

  • Participant must not have current or prior use of biologic agents for treatment of Ps or PsA

  • Participant must not have a diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA

  • Participant must not have received treatment with interleukin (IL) -17 or IL12/23 targeted monoclonal antibody (MAb) therapy

  • Female participant must not be pregnant or breastfeeding

Where This Study Took Place Tool Tip Icon

Where This Study Took Place Tool Tip Icon

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.